Furberg C D
Bowman Gray School of Medicine, Winston-Salem, North Carolina.
Postgrad Med. 1988 Feb 29;Spec No:83-9.
In clinical trials to date, only two types of treatment have been shown to have a positive effect on survival in patients after acute myocardial infarction: beta blockers in acute-phase as well as long-term therapy and thrombolytic agents administered within three to four hours of the onset of symptoms. The favorable trial results from these interventions have raised new questions of scientific and clinical significance. What is the mechanism of the favorable action? Do all patients stand to benefit from treatment? What is the optimal time for initiation of treatment? How long is the treatment beneficial? What are the risks and costs? What is the public health impact of widespread use of these interventions?
在迄今为止的临床试验中，仅有两种治疗方法被证明对急性心肌梗死后患者的生存率有积极影响：急性期及长期治疗使用的β受体阻滞剂，以及在症状发作三至四小时内使用的溶栓药物。这些干预措施取得的良好试验结果引发了具有科学和临床意义的新问题。有利作用的机制是什么？所有患者都能从治疗中获益吗？开始治疗的最佳时间是什么时候？治疗有益的时长是多久？风险和成本是多少？广泛使用这些干预措施对公共卫生有何影响？
